中晚期原发性肝癌治疗的新进展
作者:
通讯作者:
作者单位:

中南大学湘雅医院 肝脏外科,湖南 长沙 410008

作者简介:

奉建祁,中南大学湘雅医院硕士研究生,主要从事普通外科方面的研究。

基金项目:


Latest developments in the treatment of advanced hepatocellular carcinoma
Author:
Affiliation:

Department of Liver Surgery, Xiangya Hospital, Central South University, Changsha 410008, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 音频文件
  • |
  • 视频文件
    摘要:

    原发性肝癌(HCC)是消化道常见的恶性肿瘤,虽然在过去30年,中国的HCC发病率及病死率有呈现下降的趋势,但从世界范围内来讲,中国仍然是HCC大国。在HCC总体生存率得到提高的同时,中晚期HCC患者的预后仍然不尽人意,中晚期HCC治疗形势严峻。最近3年,一系列针对中晚期HCC的药物及治疗策略如雨后春笋般展现出来,极大的改善了患者的预后。笔者从目前取得阶段性成就的几大领域总结目前中晚期HCC的治疗进展。

    Abstract:

    Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive tract. Although the morbidity and mortality rates of HCC have been decreasing over the past 30 years in our country, China is still the country most afflicted by HCC worldwide. Despite the significant improvement in overall survival rate of HCC, the prognosis of patients with advanced HCC is still unsatisfactory and its treatment situation is very severe. In latest three years, a series of drugs and treatment strategies for advanced HCC have sprung up, which greatly improved the prognosis of the patients. Here, the authors summarize the progress in the treatment of advanced HCC in several fields with notable achievements.

    Fig.
    参考文献
    相似文献
    引证文献
引用本文

奉建祁,王志明.中晚期原发性肝癌治疗的新进展[J].中国普通外科杂志,2021,30(7):847-857.
DOI:10.7659/j. issn.1005-6947.2021.07.011

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2021-05-05
  • 最后修改日期:2021-06-23
  • 录用日期:
  • 在线发布日期: 2021-08-25